{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T21:35:41Z","timestamp":1780349741914,"version":"3.54.1"},"reference-count":13,"publisher":"SAABRON PRESS","issue":"1-2","license":[{"start":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T00:00:00Z","timestamp":1652227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T00:00:00Z","timestamp":1652227200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Hematol Int"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s44228-022-00003-9","type":"journal-article","created":{"date-parts":[[2022,5,11]],"date-time":"2022-05-11T15:02:28Z","timestamp":1652281348000},"page":"56-59","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Trends in Inpatient Chemotherapy Hospitalizations, Cost and Mortality for Patients with Acute Leukemias and Myeloma"],"prefix":"10.46989","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8823-2620","authenticated-orcid":false,"given":"Kellen","family":"Gil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saqib","family":"Abbasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathan","family":"Mehta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"McClune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Sborov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nausheen","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Al-Ola","family":"Abdallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddhartha","family":"Ganguly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"McGuirk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leyla","family":"Shune","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghulam Rehman","family":"Mohyuddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"26435","published-online":{"date-parts":[[2022,5,11]]},"reference":[{"key":"3_CR1","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/leu.2013.176","volume":"28","author":"M Othus","year":"2014","unstructured":"Othus M, Kantarjian H, Petersdorf S, et al. Declining rates of treatment-related mortality in patients with newly diagnosed AML given \u2018intense\u2019 induction regimens: a report from SWOG and MD Anderson. Leukemia. 2014;28:289\u201392.","journal-title":"Leukemia"},{"key":"3_CR2","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1182\/bloodadvances.2019000707","volume":"4","author":"FL Mabrey","year":"2020","unstructured":"Mabrey FL, Gardner KM, Shannon Dorcy K, et al. Outpatient intensive induction chemotherapy for acute myeloid leukemia and high-risk myelodysplastic syndrome. Blood Adv. 2020;4:611\u20136.","journal-title":"Blood Adv"},{"key":"3_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1161\/CIRCOUTCOMES.117.003846","volume":"10","author":"R Khera","year":"2017","unstructured":"Khera R, Krumholz HM. With great power comes great responsibility: big data research from the national inpatient sample. Circ Cardiovasc Qual Outcomes. 2017;10:1\u20137.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"3_CR4","unstructured":"2021 4\/24. Healthcare Cost and Utilization Project. https:\/\/www.hcup-us.ahrq.gov\/db\/ccr\/costtocharge.jsp. Accessed 24 Apr 2021."},{"key":"3_CR5","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1200\/JCO.2011.37.8018","volume":"30","author":"SP Hunger","year":"2012","unstructured":"Hunger SP, Lu X, Devidas M, et al. Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children\u2019s oncology group. J Clin Oncol. 2012;30:1663\u20139.","journal-title":"J Clin Oncol"},{"key":"3_CR6","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.1002\/cncr.29319","volume":"121","author":"ME Percival","year":"2015","unstructured":"Percival ME, Tao L, Medeiros BC, Clarke CA. Improvements in the early death rate among 9380 patients with acute myeloid leukemia after initial therapy: a SEER database analysis. Cancer. 2015;121:2004\u201312.","journal-title":"Cancer"},{"key":"3_CR7","doi-asserted-by":"publisher","first-page":"e56","DOI":"10.1093\/cid\/cir073","volume":"52","author":"AG Freifeld","year":"2011","unstructured":"Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52:e56-93.","journal-title":"Clin Infect Dis"},{"key":"3_CR8","doi-asserted-by":"publisher","first-page":"4417","DOI":"10.1200\/JCO.2011.35.7525","volume":"29","author":"RB Walter","year":"2011","unstructured":"Walter RB, Othus M, Borthakur G, et al. Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment. J Clin Oncol. 2011;29:4417\u201323.","journal-title":"J Clin Oncol"},{"key":"3_CR9","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1111\/j.1600-0404.2006.00701.x","volume":"114","author":"SK Saxena","year":"2006","unstructured":"Saxena SK, Ng TP, Yong D, Fong NP, Gerald K. Total direct cost, length of hospital stay, institutional discharges and their determinants from rehabilitation settings in stroke patients. Acta Neurol Scand. 2006;114:307\u201314.","journal-title":"Acta Neurol Scand"},{"key":"3_CR10","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1377\/hlthaff.2018.05424","volume":"38","author":"Z Cooper","year":"2019","unstructured":"Cooper Z, Craig S, Gaynor M, Harish NJ, Krumholz HM, Reenen JV. Hospital prices grew substantially faster than physician prices for hospital-based care in 2007\u201314. Health Aff. 2019;38:184\u20139.","journal-title":"Health Aff."},{"key":"3_CR11","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1056\/NEJMoa061094","volume":"356","author":"OA Cornely","year":"2007","unstructured":"Cornely OA, Maertens J, Winston DJ, et al. Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007;356:348\u201359.","journal-title":"N Engl J Med"},{"key":"3_CR12","unstructured":"2017 04\/27. FDA approves first treatment for certain types of poor-prognosis acute myeloid leukemia. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-certain-types-poor-prognosis-acute-myeloid-leukemia. Accessed 27 Apr 2021."},{"key":"3_CR13","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/ajh.25791","volume":"95","author":"SV Rajkumar","year":"2020","unstructured":"Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk-stratification and management. Am J Hematol. 2020;95:548\u201367.","journal-title":"Am J Hematol"}],"container-title":["Clinical Hematology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44228-022-00003-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s44228-022-00003-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s44228-022-00003-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T09:21:37Z","timestamp":1694424097000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s44228-022-00003-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,11]]},"references-count":13,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["3"],"URL":"https:\/\/doi.org\/10.1007\/s44228-022-00003-9","relation":{},"ISSN":["2590-0048"],"issn-type":[{"value":"2590-0048","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,11]]},"assertion":[{"value":"11 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None of authors have any conflicts of interest to declare other than the following. DS: consulting for Janssen, SkylinDx, GlaxoSmithKline, Legend Biotech, Amgen and Celgene. SG: Daiichi Sankyo: Research Funding; Seattle Genetics: Speakers Bureau; Kite Pharma: Honoraria, Other: Advisory Board; Janssen: Honoraria. JM: Kite Pharmaceuticals: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Bellicum Pharmaceuticals: Research Funding; Astellas: Research Funding; Juno Therapeutics: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding; Novartis: Research Funding; Fresenius Biotech: Research Funding; Gamida Cell: Research Funding; Pluristem Ltd: Research Funding; Articulate Science.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}